Ciprofloxacin, clinafloxacin, PD 131628, sparfloxacin, and trovafloxacin were tested against 236 strains of Streptococcus pneumoniae, most of which were resistant to other agents. Resistance to multiple antibiotics did not affect the organism's susceptibility to the fluoroquinolones. The fluoroquinolones with in vitro antipneumococcal activity might be particularly useful against strains that are resistant to the more traditional therapeutic agents.
with seven different nonquinolone compounds. The antimicrobial agents and breakpoint concentrations that were tested are shown in Table 1 . Agar dilution and disk diffusion methods were used to confirm chloramphenicol resistance among the 50 strains that grew in the presence of that drug at a concentration of 4.0 g/ml in the microdilution trays. The agar dilution MICs were 8.0 g/ml (11 strains) or 16 g/ml (39 strains), and all strains gave zones of Յ18 mm in diameter around a 30-g chloramphenicol disk.
Antibiotic susceptibility and resistance results for the isolates that were selected for this study are described in Table 1 . Erythromycin resistance occurred among 34% of the 236 isolates. All clindamycin-resistant strains (15%) were also resistant to erythromycin. All 50 chloramphenicol-resistant strains were also resistant to tetracycline. For ciprofloxacin, 90% of the strains were inhibited by Յ1.0 g/ml, 9% required MICs of 2.0 g/ml, and 1% required MICs of 4.0 g/ml. Ciprofloxacin MICs of Ն8.0 g/ml were not observed in this challenge set of pneumococci. The four other fluoroquinolones inhibited all 236 isolates at concentrations of Յ1.0 g/ml (see Table 1 for MIC ranges). The antibiotic-resistant strains were predominantly penicillin resistant or intermediate, whereas penicillin-susceptible strains were rarely resistant to the other compounds (Table 2) . Most (44 of 60) penicillin-susceptible strains were susceptible to the six other nonquinolone drugs, but only 12 of 64 penicillin-intermediate strains and 1 of 112 penicillin-resistant strains were susceptible to all the other drugs. Eighteen strains (17 penicillin resistant) were resistant or intermediate to all seven nonquinolone drugs, and 14 additional strains were susceptible to no more than one of the agents. Table 3 defines the in vitro potencies of all of the fluoroquinolones as geometric mean MICs; the newer fluoroquinolones were approximately four to eight times more active than ciprofloxacin. For pneumococci that were susceptible, intermediate, or resistant to each of seven nonquinolone antibiotics, geometric mean MICs of the fluoroquinolones did not change substantially from those calculated for all isolates combined. We concluded that resistance to any one of the seven nonquinolone drugs does not affect the potency of the fluoroquinolones to any important extent.
Penicillin-intermediate and penicillin-resistant strains of S. pneumoniae have now spread throughout the world. In 1994 and 1995, only 76% of pneumococci in the United States were susceptible to penicillin and 9.5% were resistant (MIC, Ն2.0 g/ml) (3). Relative resistance to penicillin results from alterations in penicillin-binding proteins produced by some pneumococci, and those alterations also reduce the susceptibility to many other ␤-lactam drugs (6). Resistance to non-␤-lactam drugs is also more common among penicillin-resistant strains (3, 8, 10, 11) . For that reason, there is an increased interest in alternative orally administered antimicrobial agents that might be useful for treating pneumococcal infections of the respiratory tract.
Erythromycin and the newer macrolides and azalides are likely candidates for empiric therapy of respiratory tract infections caused by S. pneumoniae. Unfortunately, most macrolideresistant pneumococci are also resistant to penicillin and many other ␤-lactams (3, 10, 11). The same observation can be made for trimethoprim-sulfamethoxazole, tetracycline, and chloramphenicol.
Ciprofloxacin has not proven to be consistently reliable for treating pneumococcal disease (2, 5, 9) . This report describes the in vitro potencies of four other fluoroquinolones against multiply resistant strains of S. pneumoniae. The relative antipneumococcal activity of these agents was clinafloxacin Ͼ trovafloxacin Ͼ PD 131628 Ͼ sparfloxacin Ͼ ciprofloxacin. Whether the differences in in vitro potency offer any important clinical advantage remains to be seen. The important conclusion drawn from our data is that the potency of the fluoroquinolones is not influenced by resistance to other agents. This observation may provide the rationale for alternative oral therapy that can be used in patient populations that are likely to be colonized with multiply resistant pneumococci. Of course, the newer fluoroquinolones must first be shown to be clinically effective in treating pneumococcal respiratory tract infections. In vitro activity is only one aspect that must be considered when addressing the question of how these drugs will be used in medical practice.
